EGF receptor variant III as a target antigen for tumor immunotherapy (Q37259602)

19 August 2017

1 reference

title

EGF receptor variant III as a target antigen for tumor immunotherapy (English)

1 reference

19 August 2017

1 reference

1 reference

Gordon Li

1

1 reference

19 August 2017

Albert J Wong

series ordinal

2

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

977-985

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

The natural history of EGFR and EGFRvIII in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Keyhole limpet hemocyanin (KLH): a biomedical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Targeting the epidermal growth factor receptor in high-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

RNA interference against a glioma-derived allele of EGFR induces blockade at G2M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Impaired capacity for upregulation of MHC class II in tumor-associated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.977

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.977

1 reference

19 August 2017

1 reference